Examkin

Question

Difficulty: HardPharmacologic Interventions

A 7272-year-old man with a history of nonvalvular atrial fibrillation, hypertension, and type 22 diabetes mellitus is evaluated in the clinic for a 44-week history of productive cough, low-grade fevers, night sweats, and a 4.54.5-kg (1010-lb) weight loss. His current medications include rivaroxaban, lisinopril, and metformin. Vital signs are temperature 37.8∘C37.8^\circ \text{C} (100.0∘F100.0^\circ \text{F}), blood pressure 132/82 mm Hg132/82 \text{ mm Hg}, heart rate 88/min88/\text{min}, and respiratory rate 16/min16/\text{min}. Physical examination reveals bronchial breath sounds and crackles in the right upper lung field. A chest radiograph demonstrates a cavitary lesion in the apical segment of the right upper lobe. Sputum acid-fast bacilli smears are positive, and a nucleic acid amplification test confirms the presence of *Mycobacterium tuberculosis*. The physician plans to initiate a daily regimen of isoniazid, rifampin, pyrazinamide, and ethambutol. Which of the following is the most appropriate management regarding this patient's anticoagulation?

  1. Discontinue rivaroxaban and initiate warfarinAnswer
  2. B
    Discontinue rivaroxaban and initiate apixaban
  3. C
    Discontinue rivaroxaban and initiate dabigatran
  4. D
    Increase the dosage of rivaroxaban
  5. E
    Discontinue rivaroxaban and initiate aspirin

Answer

The most appropriate management is to discontinue rivaroxaban and initiate warfarin.
The most appropriate management is to transition the patient from rivaroxaban to warfarin. This patient requires uninterrupted anticoagulation for stroke prophylaxis due to nonvalvular atrial fibrillation, but he also needs treatment for active tuberculosis with a regimen containing rifampin. Rifampin is a potent inducer of both cytochrome P450 3A4 (CYP3A4) and the efflux transporter P-glycoprotein (P-gp). Rivaroxaban is heavily dependent on both of these pathways for clearance. Coadministration with rifampin significantly increases the metabolism and efflux of rivaroxaban, leading to subtherapeutic plasma levels and an unacceptably high risk of thromboembolism. Because direct oral anticoagulants (DOACs) lack a routine laboratory assay for dose adjustment, they are contraindicated for use with strong dual CYP3A4/P-gp inducers. Warfarin is also metabolized by CYP enzymes (primarily CYP2C9, which is also induced by rifampin), but unlike DOACs, warfarin therapy is routinely monitored using the International Normalized Ratio (INR). The dosage can be empirically increased and carefully titrated to maintain the target therapeutic range during concurrent rifampin therapy.

Step-by-Step Solution

1
Identify the patient's underlying conditions and current treatments.
The patient has atrial fibrillation requiring uninterrupted anticoagulation (currently rivaroxaban) and new-onset active tuberculosis requiring RIPE therapy (which includes rifampin).
Establishing the concurrent therapeutic needs is the critical first step in medication reconciliation.
2
Analyze the pharmacokinetic properties of the newly prescribed antimycobacterial therapy.
Rifampin is a potent inducer of cytochrome P450 enzymes (especially CYP3A4) and the efflux transporter P-glycoprotein (P-gp).
Antimycobacterial drugs, particularly rifamycins, are notorious for precipitating significant drug-drug interactions.
3
Evaluate the interaction between the new therapy and current medications.
Direct oral anticoagulants (DOACs) like rivaroxaban are substrates for CYP3A4 and P-gp. Rifampin will drastically reduce DOAC plasma concentrations, rendering them ineffective and leading to a high risk of stroke.
DOACs cannot be used safely with strong inducers due to a lack of routine, reliable monitoring parameters to guide dose adjustment.
4
Determine the safest alternative for continued anticoagulation.
Warfarin is the most appropriate alternative. Although its metabolism is also induced by rifampin, warfarin dosing can be safely titrated using frequent INR monitoring.
Adjustable dosing guided by laboratory monitoring overcomes the unpredictability of enzymatic induction.

Key Concept

Concomitant use of direct oral anticoagulants (DOACs) and strong CYP3A4/P-glycoprotein inducers (such as rifampin) is contraindicated due to decreased anticoagulant efficacy; warfarin is preferred as it can be titrated to a therapeutic INR.
Estimated Time:1m 30s
Rate this question

Topics

Pharmacologic Interventions

More questions from this topic